The Motley Fool
21 Nov 2026, 22:15 UTC · 1h ago
Novo Nordisk's Wegovy Pill Is Capturing 80% of New Oral Obesity Prescriptions. Is NVO Stock a Buy?
Impact · against what's priced in
The news is neutral to slightly positive for Novo Nordisk as the oral Wegovy success helps offset injectable losses, though the 80% prescription share is likely already reflected in the broader analyst outlook. For Eli Lilly, the report confirms the market's current assumption of Novo's oral dominance, providing no new catalyst.
- LLY+0.00
Already priced in
- The price assumes
Oral Wegovy new-prescription share gains (~80% NBRx)





